AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11989050 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 100 micrograms i.v. 3 min before ESWL
Number of subjects: 60
Study 9803444 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal TRH treatment
Number of subjects: 297
Study 9803444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297
Study 9803444 — intervention group
Group type: COMPARATOR
Intervention: Control and TRH-treated groups
Number of subjects: 297
Study 8929933 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential services
Number of subjects: 149
Study 8929933 — intervention group
Group type: COMPARATOR
Intervention: Nonresidential services
Number of subjects: 149
Study 8929933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both residential and nonresidential services
Number of subjects: 149
Study 2551765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 mg/kg.day
Number of subjects: 20
Study 2551765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31349003 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily once or twice based on BMI) as an add-on to standard therapy
Number of subjects: 60
Study 31349003 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (SAMA + SABA inhaled and ICS + LABA or ICS + LABA + LAMA)
Number of subjects: 60
Study 28118422 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 37
Study 28118422 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 37
Study 25514794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg daily)
Number of subjects: 0
Study 25514794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: Muc1 expression in DSVPTC
Number of subjects: 60
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 expression in DSVPTC
Number of subjects: 60
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lymph node metastasis in DSVPTC
Number of subjects: 60
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: Muc1 expression in cervical lymph node metastasis group
Number of subjects: 60
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 expression in cervical lymph node metastasis group
Number of subjects: 60
Study 23898609 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Muc1 and p63 expression
Number of subjects: 60
Study 21109771 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) and Valproic Acid (VPA) combination therapy
Number of subjects: 0
Study 21109771 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA) alone
Number of subjects: 0
Study 21173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine (30 mg once daily for more than 48 weeks)
Number of subjects: 146
Study 21173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for more than 48 weeks)
Number of subjects: 146
Study 21173560 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (100 mg once daily for more than 48 weeks)
Number of subjects: 146
Study 21173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine
Number of subjects: 146
Study 21173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 146
Study 21173560 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 146
Study 17925427 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-W ramp protocol
Number of subjects: 11
Study 17925427 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-W ramp protocol
Number of subjects: 11
Study 17925427 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-W step protocol
Number of subjects: 11
Study 17925427 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-W ramp protocol
Number of subjects: 11
Study 17925427 — intervention group
Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 11
Study 16113834 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 30
Study 16113834 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 30
Study 12009718 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate concentration greater than 0.31 mmol.l(-1)
Number of subjects: 354
Study 12009718 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate concentration greater than 0.38 mmol.l(-1)
Number of subjects: 354
Study 12009718 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised urate in patients not on diuretics
Number of subjects: 354
Study 12009718 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate
Number of subjects: 354
Study 9856379 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 71
Study 9856379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg)
Number of subjects: 71
Study 9856379 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine and Lisinopril
Number of subjects: 71
Study 7893026 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with fentanyl (20 micrograms)
Number of subjects: 8
Study 7893026 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (plain)
Number of subjects: 8
Study 2588996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine with 10 ml of 1.5% lidocaine
Number of subjects: 2
Study 2588996 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (control)
Number of subjects: 2
Study 939842 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program (20 hours) involving child, parents, and teacher
Number of subjects: 32
Study 939842 — intervention group
Group type: COMPARATOR
Intervention: No contact control group
Number of subjects: 32
Study 31806076 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular CBT for youth anxiety
Number of subjects: 59
Study 31806076 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 59
Study 31405401 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated district level mental health care plan
Number of subjects: 245
Study 27966032 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 66% of individual electrical phosphene thresholds
Number of subjects: 14
Study 27966032 — intervention group
Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 0% (sham)
Number of subjects: 14
Study 27966032 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual electrical phosphene thresholds
Number of subjects: 14
Study 26212090 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual informed group
Number of subjects: 51
Study 26212090 — intervention group
Group type: COMPARATOR
Intervention: Written informed group (control)
Number of subjects: 51
Study 24261303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 30
Study 24261303 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 30
Study 24261303 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 30
Study 22093196 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg QD (2.5 mg in subjects with moderate/severe renal impairment)
Number of subjects: 16500
Study 22093196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16500
Study 19501222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal sterilization through electrocoagulation
Number of subjects: 88
Study 19501222 — intervention group
Group type: COMPARATOR
Intervention: Application of mechanical clips
Number of subjects: 88
Study 19681257 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips) and an anticavity toothpaste (Crest Cavity Protection)
Number of subjects: 46
Study 19681257 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips and a sodium fluoride (NaF) whitening dentifrice (Mentadent Whitening Toothpaste)
Number of subjects: 46
Study 19681257 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips and a sodium monofluorophosphate (MFP) whitening dentifrice (Rembrandt Low Abrasion Whitening Toothpaste)
Number of subjects: 46
Study 15563390 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (extended lateral approach with subchondral fixation, plating, and bone grafting when necessary)
Number of subjects: 244
Study 15563390 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (ice, elevation, and rest without closed reduction)
Number of subjects: 244
Study 11403755 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser‐assisted recanalization and stent implantation
Number of subjects: 212
Study 9153347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting administration of 400 mg racemic ibuprofen
Number of subjects: 0
Study 9153347 — intervention group
Group type: COMPARATOR
Intervention: Postprandial administration of 400 mg racemic ibuprofen
Number of subjects: 0
Study 7955240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rastelli operation or intraventricular repair
Number of subjects: 24
Study 3608379 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide 250 mg twice daily for 2 days
Number of subjects: 23
Study 3608379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29460783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zùsto®
Number of subjects: 10
Study 29460783 — intervention group
Group type: COMPARATOR
Intervention: Glucose 25 g
Number of subjects: 10
Study 26850799 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (10 min on each foot)
Number of subjects: 12
Study 25658956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 20 mg capsule
Number of subjects: 14
Study 25658956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon 2 mg IV infusion over 30 minutes
Number of subjects: 14
Study 25658956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (oral and IV)
Number of subjects: 14
Study 23746291 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive probabilistic modeling of EEG background for seizure detection
Number of subjects: 89
Study 20377407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose (9 microg, 0.3 mL) ID injection
Number of subjects: 257
Study 20377407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose (9 microg, 0.3 mL) IM injection
Number of subjects: 257
Study 20377407 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose (15 microg each of 3 hemagglutinin vaccine antigens in 0.5 mL) IM injection
Number of subjects: 257
Study 20377407 — intervention group
Group type: EXPERIMENTAL
Intervention: Two reduced-dose (4.5 microg, 0.15 mL) ID injections
Number of subjects: 257
Study 18540358 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid pulse therapy
Number of subjects: 0
Study 18540358 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis therapy (Plasmapheresis and Cytapheresis)
Number of subjects: 0
Study 18540358 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PE)
Number of subjects: 0
Study 18540358 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption plasmapheresis (IAPP)
Number of subjects: 0
Study 16796986 — intervention group
Group type: COMPARATOR
Intervention: 21/7 oral contraceptive regimen
Number of subjects: 114
Study 16796986 — intervention group
Group type: EXPERIMENTAL
Intervention: 168-day extended regimen of DRSP/EE
Number of subjects: 114
Study 15258964 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Number of subjects: 4
Study 11122141 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and chemotherapy (CT)
Number of subjects: 292
Study 9308808 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis (PGD) of aneuploidy for chromosomes X, Y, 13, 18, and 21
Number of subjects: 36
Study 9308808 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal embryos transferred after PGD
Number of subjects: 36
Study 8319667 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-enriched milk (12 mg/l)
Number of subjects: 153
Study 8319667 — intervention group
Group type: COMPARATOR
Intervention: Control milk (1 mg/l)
Number of subjects: 153
Study 3105357 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 15‐1788
Number of subjects: 7
Study 3105357 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 7
Study 3105357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30995895 — intervention group
Group type: EXPERIMENTAL
Intervention: Half saline-bicarbonate infusion
Number of subjects: 100
Study 30995895 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 30146142 — intervention group
Group type: EXPERIMENTAL
Intervention: ePST (computer-guided Problem-Solving Treatment)
Number of subjects: 24
Study 30146142 — intervention group
Group type: COMPARATOR
Intervention: MCC (minimal contact control group)
Number of subjects: 24
Study 30146142 — intervention group
Group type: EXPERIMENTAL
Intervention: ePST
Number of subjects: 24
Study 27236864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous acetaminophen every 6 hours for 24 hours
Number of subjects: 147
Study 27236864 — intervention group
Group type: COMPARATOR
Intervention: Comparable placebo
Number of subjects: 147
Study 25531109 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (80 mg)
Number of subjects: 1506
Study 25531109 — intervention group
Group type: COMPARATOR
Intervention: Low dose atorvastatin (10 mg)
Number of subjects: 1506
Study 22158433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d)
Number of subjects: 15
Study 22158433 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 15
Study 22158433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20477781 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin plus nitrous oxide
Number of subjects: 63
Study 20477781 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nitrous oxide
Number of subjects: 63
Study 20477781 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus air
Number of subjects: 63
Study 18539358 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emulsion foam 0.05%
Number of subjects: 958
Study 18539358 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 958
Study 15841830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for depressed older adults
Number of subjects: 34
Study 12562348 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey-impregnated gauzes
Number of subjects: 88
Study 12562348 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauzes
Number of subjects: 88
Study 12562348 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked gauzes
Number of subjects: 88
Study 12562348 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressings
Number of subjects: 88
Study 9426297 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 a.m. testing
Number of subjects: 10
Study 9426297 — intervention group
Group type: COMPARATOR
Intervention: 8 a.m. testing
Number of subjects: 10
Study 9426297 — intervention group
Group type: COMPARATOR
Intervention: 3 p.m. testing
Number of subjects: 10
Study 9426297 — intervention group
Group type: COMPARATOR
Intervention: 8 p.m. testing
Number of subjects: 10
Study 8830068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus haloperidol (20 mg/day)
Number of subjects: 12
Study 2919772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 2 mg butorphanol
Number of subjects: 40
Study 2919772 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine + 0 mg butorphanol
Number of subjects: 40
Study 2919772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine + 3 mg butorphanol
Number of subjects: 40
Study 31996813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% NaCl solution with 0.3% MSG
Number of subjects: 584
Study 31996813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% NaCl solution with 0.3% MSG
Number of subjects: 584
Study 31996813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution with 0.3% MSG
Number of subjects: 584
Study 31996813 — intervention group
Group type: COMPARATOR
Intervention: 0.3% NaCl solution without MSG
Number of subjects: 584
Study 31996813 — intervention group
Group type: COMPARATOR
Intervention: 0.6% NaCl solution without MSG
Number of subjects: 584
Study 31996813 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution without MSG
Number of subjects: 584
Study 29855444 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT)
Number of subjects: 16
Study 29855444 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 16
Study 28708734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1‐mmol/kg bw of gadoterate (full dose)
Number of subjects: 40
Study 28708734 — intervention group
Group type: COMPARATOR
Intervention: 0.05‐mmol/kg bw of gadobenate (half dose)
Number of subjects: 40
Study 25089928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor infusion (bolus plus 2-h infusion)
Number of subjects: 15
Study 25089928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg dose at 1h, 1.5h, 2h, or 2.5h after cangrelor)
Number of subjects: 15
Study 25089928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily for 5 or 6 days)
Number of subjects: 15
Study 25089928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor infusion (on study day 8)
Number of subjects: 15
Study 23949478 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic paraesophageal hernia repair (LPEHR) in group A (acute)
Number of subjects: 269
Study 23949478 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic paraesophageal hernia repair (LPEHR) in groups A, B, and C
Number of subjects: 269
Study 21223498 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) screening tool
Number of subjects: 2480
Study 19341849 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of pills at initiation, followed by counseling and a three-pack resupply
Number of subjects: 655
Study 19341849 — intervention group
Group type: COMPARATOR
Intervention: Four packs at initiation
Number of subjects: 655
Study 17986694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours)
Number of subjects: 1435
Study 17986694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study 17986694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 1435
Study 15513364 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 724
Study 15513364 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 724
Study 11695951 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg/d for 6 weeks
Number of subjects: 22
Study 11695951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9663244 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplantation of 60 mg of a diffuse hyperplastic parathyroid gland into subcutaneous forearm tissue (Group A)
Number of subjects: 46
Study 9663244 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransplantation of 15 pieces (60 mg) of 1 mm3 tissue into forearm muscles (Group B)
Number of subjects: 46
Study 9663244 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate and calcitriol prescribed post-operation
Number of subjects: 46
Study 8148460 — intervention group
Group type: EXPERIMENTAL
Intervention: poly(I).poly(C12U)
Number of subjects: 92
Study 3542628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole
Number of subjects: 54
Study 3542628 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 54
Study 29518703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored driving lessons (two one-hour lessons)
Number of subjects: 57
Study 29518703 — intervention group
Group type: COMPARATOR
Intervention: Road rules refresher course only (control group)
Number of subjects: 57
Study 26036929 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred nutrition intervention
Number of subjects: 80
Study 26036929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 24866357 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (PR)
Number of subjects: 58
Study 24866357 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study 22375580 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention group (n = 204)
Number of subjects: 310
Study 22375580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable and Fruit (VF) intervention group (n = 106)
Number of subjects: 310
Study 20629484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild traumatic brain injury (MTBI)
Number of subjects: 43
Study 20629484 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study 20629484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MTBI
Number of subjects: 43
Study 18179466 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of immigrants
Number of subjects: 283
Study 18179466 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver language preference
Number of subjects: 283
Study 18179466 — intervention group
Group type: EXPERIMENTAL
Intervention: Immigrant status and language preference
Number of subjects: 283
Study 18027541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 50
Study 15613018 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg quercetin‐4'‐O‐beta‐D‐glucoside
Number of subjects: 0
Study 15613018 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg quercetin‐4'‐O‐beta‐D‐glucoside
Number of subjects: 0
Study 15613018 — intervention group
Group type: COMPARATOR
Intervention: Collagen-stimulated platelet activation
Number of subjects: 0